Review
Immunology
Swayanka Biswas, Katja Bieber, Rudolf Armin Manz
Summary: IL-10 is a cytokine that has pleiotropic effects on immune cells, including both suppressive and activating functions. It plays a dual role in Systemic lupus Erythematosus (SLE), inhibiting pro-inflammatory effector functions while also promoting extrafollicular antibody response. IL-10 is produced by B cells, myeloid cells, and certain T cell subsets, and it drives B cell responses, proliferation, class switching, and plasma cell formation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Tomohiro Koga, Kunihiro Ichinose, Atsushi Kawakami, George C. Tsokos
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease with IL-17-producing cells playing a key role in its pathogenesis, making them a therapeutic target. Targeting IL-17 for treatment shows promising potential.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Riham Abdel-Hamid Haroun, Rasha A. Abdel Noor
Summary: This study aimed to investigate the association between the IL-8-251 T/A polymorphism and the risk of SLE. The results showed that carriers of the AA genotype had a significantly increased risk of SLE, and the A allele frequency was also significantly higher in SLE patients. Additionally, IL-8 was found to interact significantly with key members of the SLE signaling pathway.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Yantong Zhu, Xiaojun Tang, Yang Xu, Si Wu, Weilin Liu, Linyu Geng, Xiaolei Ma, Betty P. Tsao, Xuebing Feng, Lingyun Sun
Summary: Systemic lupus erythematosus (SLE) is characterized by the production of pathogenic autoantibodies. This study found that Ribonuclease A family member 2 (RNase2) is highly expressed in SLE patients and is associated with the increase of autoreactive B cells known as age-associated B cells (ABCs). Reduction of RNASE2 expression led to a decrease in ABCs, accompanied by a reduction in total IgG and IL-10 levels. It was also found that both RNASE2 and IL-10 in SLE patients were mainly derived from monocytes. The study concluded that RNASE2 might induce the production of ABCs via IL-10 secreted from monocytes, contributing to the pathogenesis of SLE.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Patricia Richter, Luana Andreea Macovei, Ioana Ruxandra Mihai, Anca Cardoneanu, Maria Alexandra Burlui, Elena Rezus
Summary: Systemic lupus erythematosus (SLE) is a complex autoimmune disorder in which cytokines, such as TNF-alpha and IL-17, play crucial roles. The modulation of these cytokines may impact disease progression and serve as potential biomarkers. Elevated levels of TNF-alpha and IL-17 are associated with high disease activity in SLE patients, although their inhibition as a treatment option is still under discussion. Further studies are needed to explore the therapeutic potential of targeting these cytokines in SLE.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Julie Sarrand, Muhammad Soyfoo
Summary: IL-33 is a newly discovered cytokine that acts as an alarmin to alert the innate immune system following cell death or necrosis. It has been found to be significantly upregulated in patients with SLE and lupus nephritis, suggesting its involvement in the pathology of SLE.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Mengmeng Xiang, Yang Feng, Yilun Wang, Jie Wang, Zhixiong Zhang, Jun Liang, Jinhua Xu
Summary: This meta-analysis revealed that the circulating level of interleukin-18 is significantly higher in systemic lupus erythematosus (SLE) patients compared to healthy controls. Patients with higher SLEDAI scores, Asian, White, Arab, or mixed ethnicity tend to have elevated levels of IL-18, indicating the potential role of IL-18 in the pathogenesis of SLE.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Xiaomin Zhang, Chang Liu, Jieli Yang, Hefei Ren, Jiafeng Zhang, Sai Chen, Jigang Ren, Lin Zhou
Summary: This study identified IL-1RA as a biomarker for diagnosing SLE, while IL-10 and LIF can be indicators to discriminate between active and inactive SLE.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Fatima K. Alduraibi, Kathryn A. Sullivan, Hui-Chen Hsu, W. Winn Chatham, John D. Mountz
Summary: Elevated IFNy and IL-17 levels were found in SLE patients, correlated with autoantibody production, while elevated IL-10 levels were associated with LN. LN patients had higher plasma levels of anti-DNA and anti-Sm/RNP. Decreased levels of anti-Sm/RNP were associated with acute mucocutaneous manifestations.
CLINICAL IMMUNOLOGY
(2023)
Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Xin Jin, Jia Chen, Jian Wu, Ying Lu, Baohua Li, Wenning Fu, Wei Wang, Dawei Cui
Summary: This study found significant differences in the frequency of cTfh cell subsets and associated B cell subsets between active and inactive SLE patients, with elevated levels of cytokines associated with cTfh cells in active SLE patients. Additionally, Tfh cell subsets and plasmablasts may have important roles in the pathogenesis of SLE and could be potential targets for therapeutic interventions.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Xin Gao, Jing He, Xiaolin Sun, Fangting Li
Summary: A mathematical model was developed to simulate the treatment process of systemic lupus erythematosus (SLE), and an effective range of interleukin-2 (IL-2) dosage was defined based on T cell ratio. Additionally, a classification method based on the pre-treatment cell ratio was proposed to predict the treatment outcome.
Review
Oncology
Kaichi Kaneko, Hao Chen, Matthew Kaufman, Isaak Sverdlov, Emily M. Stein, Kyung-Hyun Park-Min
Summary: Osteonecrosis is a complex and devastating complication of systemic lupus erythematosus, with variable prevalence in SLE patients. The use of high-dose glucocorticoid therapy is strongly associated with the development of osteonecrosis in SLE patients, although the exact pathophysiology and risk factors for osteonecrosis in this population are not fully understood.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Immunology
Suqing Zhou, Qianwen Li, Shengnan Zhou, Ming Zhao, Liwei Lu, Haijing Wu, Qianjin Lu
Summary: The article introduces a humanized murine model that successfully induces rapid-onset cutaneous lupus, revealing the potential role of age-associated B cells and the localized antibody production in the disease.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Chemistry, Multidisciplinary
Shunxiang Li, Huihua Ding, Ziheng Qi, Jing Yang, Jingyi Huang, Lin Huang, Mengji Zhang, Yuanjia Tang, Nan Shen, Kun Qian, Qiang Guo, Jingjing Wan
Summary: Serum metabolic fingerprints can be used for disease diagnosis and biomarker discovery. By analyzing the serum metabolic fingerprints of systemic lupus erythematosus (SLE) patients and healthy controls, early diagnosis and precision medicine for SLE can be achieved. This study identified the unique metabolic pattern of SLE patients and screened out a panel of metabolic biomarkers.